Astrazeneca ADR Stock
Your prediction
Astrazeneca ADR Stock
Astrazeneca ADR gained 0.710% compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Astrazeneca ADR | 0.710% | 6.818% | 11.905% | 6.015% | 14.634% | 66.274% | - |
Bayer AG ADR | 4.480% | 0.752% | -3.597% | -54.110% | -22.093% | -49.242% | -55.034% |
Novo Nordisk A/S ADR | -0.420% | 0.424% | -0.837% | -22.039% | 26.333% | 92.997% | 168.100% |
Roche Holding AG ADR | 0.680% | -2.526% | -4.330% | -19.342% | -12.529% | -16.850% | - |
News
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN)Q1 2024 Earnings CallApr 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com